COVID-19大流行对美国与加拿大阿片类药物过量及其他不良事件影响的系统综述
该系统综述检索2020年3月至2021年12月发表的文献,比较COVID-19前后美国与加拿大阿片使用相关结局。纳入20项研究,多数显示阿片相关急诊利用增加,芬太尼尿检阳性率上升。
要点
- 阿片相关急诊利用在多数研究中增加,服务呼叫增幅17%至61%,急诊就诊增幅42%至122%。
- 芬太尼尿检阳性率在所有研究中上升,增幅34%至138%。
- 纳洛酮发放变化不一致,一项研究无变化,另一项下降。
核心结论
- COVID-19疫情初期,阿片危机替代指标显著上升,需加强预防、治疗和减害工作。
研究设计与样本
- 系统综述,检索MEDLINE via PubMed、EMBASE和CENTRAL,纳入2020年3月至2021年12月发表的同行评议文章,比较COVID-19前后美国与加拿大阿片使用相关结局,共纳入20项研究。
主要发现
- 13项(65%)研究分析服务利用,6项(30%)分析尿检结果,2项(10%)分析纳洛酮发放。
- 阿片相关急诊利用在85%(11/13)的研究中增加,服务呼叫增幅17%至61%,急诊就诊增幅42%至122%。
- 芬太尼尿检阳性率在所有6项研究中增加,增幅34%至138%;海洛因在80%(4/5)研究中增加,变化-12%至62%;羟考酮在75%(3/4)研究中增加,变化0%至44%。
- 纳洛酮发放一项研究无变化,一项研究下降。
临床怎么用
- 临床应关注疫情期间阿片相关急诊利用和芬太尼阳性率上升,加强预防、治疗和减害措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The COVID-19 pandemic impacted healthcare beyond COVID-19 infections. A better understanding of how COVID-19 worsened the opioid crisis has potential to inform future response efforts. OBJECTIVE: To summarize changes from the COVID-19 pandemic on outcomes regarding opioid use and misuse in the USA and Canada. EVIDENCE REVIEW: We searched MEDLINE via PubMed, EMBASE, and CENTRAL for peer-reviewed articles published between March 2020 and December 2021 that examined outcomes relevant to patients with opioid use, misuse, and opioid use disorder by comparing the period before vs after COVID-19 onset in the USA and Canada. Two reviewers independently screened studies, extracted data, assessed methodological quality and bias via Newcastle-Ottawa Scale, and synthesized results. FINDINGS: Among 20 included studies, 13 (65%) analyzed service utilization, 6 (30%) analyzed urine drug testing results, and 2 (10%) analyzed naloxone dispensation. Opioid-related emergency medicine utilization increased in most studies (85%, 11/13) for both service calls (17% to 61%) and emergency department visits (42% to 122%). Urine drug testing positivity results increased in all studies (100%, 6/6) for fentanyl (34% to 138%), most (80%, 4/5) studies for heroin (-12% to 62%), and most (75%, 3/4) studies for oxycodone (0% to 44%). Naloxone dispensation was unchanged and decreased in one study each. INTERPRETATION: Significant increases in surrogate measures of the opioid crisis coincided with the onset of COVID-19. These findings serve as a call to action to redouble prevention, treatment, and harm reduction efforts for the opioid crisis as the pandemic evolves. PROSPERO REGISTRATION NUMBER: CRD42021236464.
引用
- Simha S, Ahmed Y, Brummett CM, et al. Impact of the COVID-19 pandemic on opioid overdose and other adverse events in the USA and Canada: a systematic review. Reg Anesth Pain Med. 2022. PMID: 36202619. doi:10.1136/rapm-2022-103591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。